Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying ART0380, an investigational oral drug that targets ATR kinase, in people with advanced or metastatic solid tumors, including ovarian, peritoneal, fallopian tube, endometrial, colorectal, pancreatic, and acinar cell cancers. This open-label Phase IIIa trial aims to find the recommended dose of ART0380 alone and in combination with gemcitabine or irinotecan, to understand its side effects, and to evaluate its preliminary effectiveness in treating cancers that may have DNA repair defects or loss of ATM protein expression. Participants may receive ART0380 either alone or combined with gemcitabine or irinotecan in 21-day treatment cycles. ART0380 is given orally either intermittently or continuously, while gemcitabine is given on days 1 and 8, and irinotecan is infused on days 1 and 8 of each cycle. The study has multiple parts, including dose escalation phases and expansion cohorts targeting specific cancer types or genetic profiles. Some parts compare ART0380 plus gemcitabine to gemcitabine alone, while others explore ART0380 with irinotecan or as monotherapy. Throughout the study, participants will undergo regular assessments including imaging scans to evaluate tumor response by RECIST criteria, blood tests for tumor markers, and safety monitoring for side effects. Pharmacokinetics of ART0380 will be measured to understand drug levels and metabolism. Follow-up for progression-free survival and overall survival will continue for up to two years or more. Participants are expected to adhere to study visits and procedures, with performance status and organ function closely monitored during the trial.
Actively Recruiting
Researchers are evaluating a treatment for advanced breast cancer characterized by positive estrogen receptors, negative HER2 status, and mutations in the ESR1 gene. This study focuses on patients whose cancer has progressed despite prior endocrine therapy and treatment with CDK46 inhibitors. The main goal is to assess how well the combination of elacestrant and everolimus works compared to elacestrant alone in controlling the disease. Participants will be randomly assigned to one of two groups. One group receives daily oral doses of elacestrant and everolimus, while the other receives elacestrant plus a placebo resembling everolimus. Treatment continues in 28-day cycles until the disease progresses, unacceptable side effects occur, or other reasons lead to stopping treatment. After stopping, patients enter a follow-up period lasting up to 12 months where survival and new treatments are tracked every three months. During the study, patients will undergo tumor assessments, clinical evaluations, and quality-of-life questionnaires. Researchers will monitor treatment effects, side effects, and changes in health status. Safety is closely observed through regular tests including blood work and heart function monitoring. The total participation duration may extend up to about a year from treatment start to study completion.
Actively Recruiting
This research aims to create a national registry for patients suffering from parietal endometriosis, a condition involving nodules in the abdominal wall. It is conducted by a multidisciplinary radiosurgery team and focuses on patients treated with either surgical removal or percutaneous cryoablation. The study will follow participants for three years after treatment to gather comprehensive data on this condition. Patients with parietal endometriosis will be recorded in the registry based on their treatment type either cryoablation or surgery. The study does not involve experimental treatment but observes patients undergoing these procedures. The registry will collect information throughout the treatment and follow-up period, capturing data at multiple time points including one month, six months, one year, two years, and three years after treatment. Participants will be monitored regularly with clinical evaluations, imaging tests such as MRI and ultrasound, and quality of life questionnaires to assess treatment effects and complications. The study will track the epidemiology, imaging characteristics, aesthetic impact, complication rates, and recurrence of nodules. Safety assessments and quality of life measures will be collected throughout the three-year follow-up to understand long-term outcomes of the treatments.